Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan

Malaria Journal

Volumn 4, Issue , 2005, Pages

  Van Den Broek, Ingrid ^a,c   Amsalu, Ribka ^b   Balasegaram, Manica ^a,b   Hepple, Pamela ^b   Alemu, Engudaye ^b   Hussein, El Badri ^b   Al Faith, Muhammed ^b   Montgomery, Jacqui ^d   Checchi, Francesco ^c  

^a MSF UK   (United Kingdom)

^b MSF UK   (United Kingdom)

^c EPICENTRE   (France)

^d QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMISIN DERIVATIVE; ARTESUNATE; FANSIDAR; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PYRIMETHAMINE; SESQUITERPENE; SULFADOXINE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEVER; FOLLOW UP; GAMETOCYTE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; REMISSION; SUDAN; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MALARIA, FALCIPARUM; STANDARDS;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PYRIMETHAMINE; SESQUITERPENES; SUDAN; SULFADOXINE;

EID: 18044393407     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-4-14     Document Type: Article

References (25)

1. RBM: RBM in Sudan progress report, 2002: Achievements, constraints and challenges. Republic of the Sudan Federal Ministry of Health National Malaria Control Programme 2003 [http://www.emro.who.int/rbm/SUDProgReport02.pdf].
2. NMA/UNICEF: Report on Sentinel sites. Khartoum. National Malaria Administration 1999.
3. Guthmann JP, Cetre C, Suzan F: Field research, relief work and war: does chloroquine-resistance occur in displaced populations of southern Sudan? Trop Doct 1996, 26:89-90.
4. van den Broek I, Gatkoi T, Lowoko B: Chloroquine, sulfadoxine- pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, South Sudan. Trans R Soc Trop Med Hyg 2003, 97:229-235.
5. Bachy C, Checchi F, Cavalier P: Chloroquine and sulfadoxine-pyrimethamine drug sensitivity study for the treatment of uncomplicated malaria due to Plasmodium falciparum. Report Epicentre/MSF-Belgium, Mapel, Sudan 2003.
6. Stivanello E, Cavailler P, Cassano F: Efficacy of Chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum in Kajo Keji country, Sudan. Trop Med Int Health in press.
7. Anderson TJC, Nair S, Jacobzone C: Molecular assessment of drug resistance in P. falciparum from Bahr El Gazal Province, Sudan. Trop Med Int Health 2003, 8:1068-1073.
8. Adam I, Osman ME, Elghzali G, Ahmed GI, Gustafssons LL, Elbashir MI: Efficacies of Chloroquine, sulfadoxine-pyrimethamine and quinine in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol 2004, 98:661-666.
9. Khartoum conference: Treatment Options against malaria in Sudan. Federal Ministry of Health, WHO, MSF, Khartoum; 2003.
10. WHO: Position of WHO's Roll Back Malaria Department on malaria treatment policy. 2003 [http://www.emro.who.int/rbm/WHOPositionStatement.pdf].
11. MSF Access to Essential Medicine Campaign: ACT now to get malaria treatment that works to Africa. 2003 [http://www/msf.org/content/page.cfm? articleid=07B8A833-723F-4350-9D6A6412EAF51284]. Printed Editions Européennes, Brussels,Belgium
12. WHO: Assessment of Therapeutic Efficacy of Antimalarial Drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO/MAL/96.1077 1996.
13. WHO: Assessment and Monitoring of Antimalarial Drug Efficacy for the treatment of uncomplicated Falciparum malaria. WHO/HTM/RBM/2003.50 2003.
14. Snounou G, Zhu X, Siripoon N., Jarra W, Thaithong S, Brown KN, Viriyakosol S: Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 1999, 93:369-374.
15. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G: Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 2003, 68:133-139.
16. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ: Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 2004, 48:1329-1334.
17. Bosman A, Malaria Policy and Strategy Team Roll Back Malaria Department: ACT policy & forecast. Presentation at DNDi FACT Project Consultation, Geneva 2004.
18. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, Ford N, Hook C, Checchi F: Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Trans Roy Soc Trop Med Hyg in press.
19. Adjuik M, Agnamey P, Babiker A: Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial. Lancet 2002, 359:1365-1372.
20. Bloland P: Drug resistance in Malaria. WHO/CDS/DRS/2001.4 2001.
21. von Seidlein L, Milligan P, Pinder M: Efficacy of artesunate plus pyrimethamine-sulfadoxine for uncomplicated falciparum malaria in Gambian children: a double blind, randomized, controlled trial. Lancet 2000, 355:352-357.
22. Krishna S, White NJ: Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996, 30:263-299.
23. NMCP: Monitoring antimalarial resistance. In Unpublished report National Malaria, Schistosomiasis and Leishmaniasis Control Programme, Khartoum; 2002.
24. Malaria Symposium: ACT NOW. Columbia University, New York, Joint statement co-organizers (WHO, Unicef, MSF, the Mailman School of Public Health of Columbia University) 2004.
25. Global Fund: Global Fund commitments to improve international malaria treatment. Conclusions of a consultation among the Global Fund, WHO and members of the scientific community 2004 [http://www.theglobalfund.org/pdf/ annex_a_globalfund_commitments1.pdf].